Tacrolimus treatment in reproductive failures

Area of Science:

• Reproductive Immunology
• In Vitro Fertilization (IVF)
• Immunotherapy

Background:

• Repeated implantation failure (RIF) affects IVF success, with a significant portion potentially linked to immune factors.
• Tacrolimus, a calcineurin inhibitor, has been explored for immunotherapy in RIF for about a decade.
• Previous studies reported clinical pregnancy rates around 64% with tacrolimus treatment for RIF.

Purpose of the Study:

• To re-evaluate the efficacy of tacrolimus immunotherapy in patients with RIF.
• To assess the prevalence of immune-mediated rejection markers in RIF cases.
• To explore potential expanded indications for tacrolimus in obstetric complications.

Main Methods:

• Retrospective analysis of clinical pregnancy rates in RIF patients treated with tacrolimus.
• Assessment of Th1/Th2 cell ratios to identify immune-mediated rejection.
• Review of existing literature on tacrolimus in RIF and related obstetric conditions.

Main Results:

• A recent cohort demonstrated a clinical pregnancy rate of 57.1% with tacrolimus treatment for RIF.
• Approximately 35.9% of RIF cases exhibited Th1/Th2 cell ratios indicative of immune-mediated rejection.
• Tacrolimus also shows potential in managing recurrent pregnancy loss (RPL) and preventing obstetric complications.

Conclusions:

• Tacrolimus immunotherapy remains a viable option for RIF, achieving high pregnancy rates.
• A significant proportion of RIF cases have an immune basis, supporting immunomodulatory treatment.
• Further confirmatory trials are needed to establish tacrolimus's role in RIF and other obstetric conditions.